Sublingual triazolam
Home A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Sublingual triazolam



Flumazenil Reversal of Sublingual Triazolam A Randomized

9.14.2017 | Victoria Lawman
Sublingual triazolam
Flumazenil Reversal of Sublingual Triazolam A Randomized

Incremental sublingual triazolam has emerged as a popular sedation technique. Nevertheless, little research has evaluated the technique's safety or efficacy.

Exclusion criteria included a medical history significant for systemic disease (American Society of Anesthesiologists, ASA Class II or greater), use of benzodiazepines, anxiolytics or any other medications that would interact with either triazolam or flumazenil metabolism or clinical effect (including herbals) within four weeks of the study, body mass index (BMI) no less than 15 kg/m2 and no greater than 30 kg/m2, pregnancy or not currently using pharmacologic methods of birth control, allergy or sensitivity to benzodiazepines, history of a seizure disorder and chronic tobacco use.

Premedication with sublingual triazolam compared with oral

5.10.2017 | Natalie Carter
Sublingual triazolam
Premedication with sublingual triazolam compared with oral

Abstract. The clinical effects of a new administration form of triazolam, 0.2 mg sublingual (sl) tablet, were compared with those of a 10 mg tablet.

Ten patients (20%) in the triazolam group and one in the diazepam group were assessed to be too sedated during the operation. At 75 min after premedication and after the operation triazolam 0.2 mg caused deeper sedation than diazepam 10 mg according to the observer (P < 0.001, P < 0.01) and according to the patient (P < 0.01, P < 0.05).

Sublingual triazolam for the provision of anxiolysis in the dental

12.17.2017 | Victoria Lawman
Sublingual triazolam
Sublingual triazolam for the provision of anxiolysis in the dental

Both proponents and critics of the provision of powdered doses of sublingual triazolam agree that demand exists for the relief of anxiety during outpatient dental.

These studies have used different formulation and protocols of incremental dosing that do not correspond to clinical practice. To date, pharmacokinetic studies of sublingual administration have not been relevant to clinical practice, primarily because this research has only been performed upon healthy volunteers.

Ten adult volunteers received sublingual triazolam (0.25 mg) followed by additional doses after 60 (0.50 mg) and 90 (0.25 mg) minutes.

Flumazenil reversal of sublingual triazolam a randomized controlled

8.13.2017 | Nicholas Babcock
Sublingual triazolam

BACKGROUND: Incremental sublingual (SL) dosing of triazolam has emerged as a popular sedation technique. Nevertheless, few studies have evaluated the.

A single intraoral injection of flumazenil (0.2 mg) cannot immediay reverse oversedation with triazolam. A higher dose might be effective. Reversal for the purpose of discharging the patient early is neither appropriate nor safe.

The authors conducted a randomized controlled clinical trial to investigate how intraoral submucosal flumazenil (0.2 milligram) attenuates central nervous system depression produced by incremental SL dosing of triazolam (three doses of 0.25 mg across 90 minutes) in 14 adults. The authors assessed outcomes by using the Observer's Assessment of Alertness/Sedation (OAA/S) scale, bispectral index (BIS) and physiological monitoring.

Warning: The NCBI web site requires JavaScript to function. more.

Generate a file for use with external citation management software.

Given its popularity, an easily administered rescue strategy is needed. Incremental sublingual (SL) dosing of triazolam has emerged as a popular sedation technique. Nevertheless, few studies have evaluated the technique's safety or efficacy.

The OAA/S and BIS scores increased after the flumazenil injection at the 30-minute observation point, but they were not sustained. Six hours after the initial dose of triazolam had been administered (four hours after the flumazenil or placebo challenge), all patients could be discharged from the dental clinic.

National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA.

The reversal did not persist. Deep sedation from incremental SL dosing of triazolam is incompley reversed by a single intraoral injection of flumazenil. The authors discharged the patients from the dental clinic at 360 minutes.

Enhanced bioavailability of triazolam following sublingual versus

7.12.2017 | Victoria Lawman
Sublingual triazolam

The rate and extent of the absorption of triazolam following sublingual and oral administration were evaluated in this study. Eight healthy volunteers received.

National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA. National Center for Biotechnology Information, U.S.

Generate a file for use with external citation management software.

Warning: The NCBI web site requires JavaScript to function. more.

No significant differences between sublingual and oral administration were found for the elimination half-life of triazolam (4.1 vs 3.7 hr) and the time of peak concentration (1.22 vs 1.25 hr) after dose. 1). 025). The mean total area under the curve for sublingual administration was significantly larger than that following oral dosage (28.9 vs 22.6 ng-hr/mL, P less than. The rate and extent of the absorption of triazolam following sublingual and oral administration were evaluated in this study. Thus, the bioavailability of triazolam after sublingual administration is increased by an average of 28% compared with oral administration of the same dose, possibly because first-pass extraction is bypassed. The peak plasma concentration after sublingual dosage was also higher than after oral administration (4.7 vs 3.9 ng/mL, P less than. Eight healthy volunteers received triazolam 0.5 mg in a commercially available tablet, by sublingual and oral routes on two occasions in random sequence. Plasma triazolam concentrations during 24 hours after each dose were measured by electron-capture gas-liquid chromatography. Clinical effects of triazolam may likewise be enhanced by sublingual dosage.